폐동맥고혈압의 진단과 평가
Diagnosis and assessment of pulmonary arterial hypertension
2
조회
0
다운로드
5
인용
0
참고문헌
초록
The diagnosis and assessment of pulmonary arterial hypertension (PAH) is a rapidly evolving area, with changes occurring in the definition of the disease, screening and diagnostic techniques, and staging and follow-up assessment. After 4th World Symposium on pulmonary hypertension (PH) which took place in Dana Point in early 2008, the definition of PH has been simplified (mean pulmonary artery pressure ≥25 mmHg) based on currently available evidences. The diagnosis of PH involves two stages: detection (determining the cause of a patient’s symptoms, or to detect the presence of PAH in a high-risk patient) and characterization (determining the specific clinical context of the PH, including causal factors, associated diseases or substrates and hemodynamic perturbations). Echocardiography and right heart catheterization have been main diagnostic method in PAH. Also, there has been progress in imaging techniques and biomarkers used to screen patients for the disease and to follow up their response to therapy. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, and so on. As new therapies have been developed for PAH,screening, prompt diagnosis, and accurate assessment of disease severity have become increasingly important. A clear definition of PH and the development of a rational approach to diagnostic assessment and follow-up using both conventional and new tools will be essential to advance proper treatment of patients.
Abstract
The diagnosis and assessment of pulmonary arterial hypertension (PAH) is a rapidly evolving area, with changes occurring in the definition of the disease, screening and diagnostic techniques, and staging and follow-up assessment. After 4th World Symposium on pulmonary hypertension (PH) which took place in Dana Point in early 2008, the definition of PH has been simplified (mean pulmonary artery pressure ≥25 mmHg) based on currently available evidences. The diagnosis of PH involves two stages: detection (determining the cause of a patient’s symptoms, or to detect the presence of PAH in a high-risk patient) and characterization (determining the specific clinical context of the PH, including causal factors, associated diseases or substrates and hemodynamic perturbations). Echocardiography and right heart catheterization have been main diagnostic method in PAH. Also, there has been progress in imaging techniques and biomarkers used to screen patients for the disease and to follow up their response to therapy. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, and so on. As new therapies have been developed for PAH,screening, prompt diagnosis, and accurate assessment of disease severity have become increasingly important. A clear definition of PH and the development of a rational approach to diagnostic assessment and follow-up using both conventional and new tools will be essential to advance proper treatment of patients.
참고문헌 (41)
- Simonneau G, "Clinical classification of pulmonary hypertension", J Am Coll Cardiol, 43(12), pp.5S~12S (2004)
- Badesch DB, "Diagnosis and assessment of pulmonary arterial hypertension", J Am Coll Cardiol, 54(1), pp.S55~56 (2009)
- Yu PN, "Distensibility characteristics of the human pulmonary vascular bed: study of the pressure-volume response to exercise in patients with and without heart disease", Circulation, 35, pp.710~723 (1967)
- Harris P, "The relation between pressure and flow in the pulmonary circulation in normal subjects and in patients with chronic bronchitis and mitral stenosis", Cardiovasc Res, 2, pp.73~83 (1968)
- Emirgil C, "Pulmonary circulation in the aged", J Appl Physiol, 23, pp.631~640 (1967)
- Gurtner HP, "Normal values for pulmonary hemodynamics at rest and during exercise in man", Prog Resp Res, 6, pp.295~315 (1975)
- Kubicek F, "Comparison of supine and sitting body position during a triangular exercise test. I. Experiences in healthy subjects", Eur J Appl Physiol Occup Physiol, 36, pp.275~283 (1977)
- Thadani U, "Hemodynamics at rest and during supine and sitting bicycle exercise in normal subjects", Am J Cardiol, 41, pp.52~59 (1978)
- Hossack KF, "Maximal cardiac output during upright exercise: approximate normal standards and variations with coronary heart disease", Am J Cardiol, 46, pp.204~212 (1980)
- Higginbotham MB, "Regulation of stroke volume during submaximal and maximal upright exercise in normal man", Circ Res, 58, pp.281~291 (1986)
- Reeves JT, "Operation Everest II: preservation of cardiac function at extreme altitude", J Appl Physiol, 63, pp.531~539 (1987)
- Janosi A, "Pulmonary artery pressure and oxygen consumption measurement during supine bicycle exercise", Chest, 93, pp.419~421 (1988)
- Stanek V, "The effect of age on the pressureflow relationship and on the capacity of pulmonary vascular bed with special reference to the condition of high flow", Prog Respir Res, 5, pp.375~384 (1970)
- Elstein D, "Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease", Lancet, 351, pp.1544~1546 (1998)
- Brecker SJ, "Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension", Br Heart J, 72, pp.384~389 (1994)
- Vachiéry JL, "False-positive diagnosis of pulmonary hypertension by Doppler echocardiography", Eur Respir J, 12, pp.1476~1478 (1998)
- Barst RJ, "Diagnosis and differential assessment of pulmonary arterial hypertension", J Am Coll Cardiol, 43(12), pp.40S~47S (2004)
- Nagaya N, "Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension", Circulation, 102, pp.865~870 (2000)
- Himelman RB, "Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease", Circulation, 79, pp.863~871 (1989)
- Grunig E, "Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene", Circulation, 102, pp.1145~1150 (2000)
- D’Alonzo GE, "Survival in patients with primary pulmonary hypertension: results from a national prospective registry", Ann Intern Med, 115, pp.343~349 (1991)
- Stupi AM, "Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis", Arthritis Rheum, 29, pp.515~524 (1986)
- Kuhn KP, "Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol", Am J Respir Crit Care Med, 167, pp.580~586 (2003)
- Kawut SM, "Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis", Chest, 123, pp.344~350 (2003)
- Hopkins WE, "Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome", J Heart Lung Transplant, 15, pp.100~105 (1996)
- Humbert M, "Pulmonary arterial hypertension in France: results from a national registry", Am J Respir Crit Care Med, 173, pp.1023~1030 (2006)
- Shapiro SM, "Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion", J Am Coll Cardiol, 30, pp.343~349 (1997)
- Sitbon O, "Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival", J Am Coll Cardiol, 40, pp.780~788 (2002)
- Galie N, "A meta-analysis of randomized controlled trials in pulmonary arterial hypertension", Eur Heart J, 30, pp.394~403 (2009)
- McLaughlin VV, "Survival in primary pulmonary hypertension: the impact of epoprostenol therapy", Circulation, 106, pp.1477~1482 (2002)
- Sitbon O, "Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension", Circulation, 111, pp.3105~3111 (2005)
- Raymond RJ, "Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension", J Am Coll Cardiol, 39, pp.1214~1219 (2002)
- Yeo TC, "Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension", Am J Cardiol, 81, pp.1157~1161 (1998)
- Forfia PR, "Tricuspid annular displacement predicts survival in pulmonary hypertension", Am J Respir Crit Care Med, 174, pp.1034~1041 (2006)
- Miyamoto S, "Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing", Am J Respir Crit Care Med, 161, pp.487~492 (2000)
- Wensel R, "Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing", Circulation, 106, pp.319~324 (2002)
- Nagaya N, "Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension", Circulation, 102, pp.865~870 (2000)
- Williams MH, "Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma- associated pulmonary arterial hypertension", Eur Heart J, 27, pp.1485~1494 (2006)
- McLaughlin VM, "ACCF", AHA clinical expert consensus document on pulmonary hypertension : a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, 2009, pp.53, 1573~1619
- Hoeper MM, "Goal-oriented treatment and combination therapy for pulmonary arterial hypertension", Eur Respir J, 26, pp.858~863 (2005)
- Provencher S, "Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension", Eur Heart J, 27, pp.589~595 (2006)